

Supplementary Table 1. Other secondary and associated efficacy points

Variable	SU users (n=87)	SU nonusers (n=17)	Total (n=104)	Between-group difference SU users vs. SU nonusers
HbA1c ≤6.5% at week 12	9 (10.3)	1 (5.9)	10 (9.6)	1.000
HbA1c ≤6.5% at week 24	8 (9.2)	2 (11.8)	10 (9.6)	0.666
Daily insulin doses, IU				
Baseline	10.24±0.89	10.12±0.49	10.22±0.84	-4.06 (-10.63 to 2.51), P=0.223
Week 24	18.02±12.35	21.82±13.47	18.64±12.55	
3-Day mean FPG, mmol/L				
Baseline	9.28±2.59	9.26±2.30	9.28±2.53	
Week 12	6.50±1.71	6.80±1.28	6.55±1.65	
Week 24	6.56±1.55	6.58±1.29	6.57±1.50	
Changes from baseline to week 12	-2.89±2.50	-2.46±2.01	-2.81±2.42	-0.37 (-1.18 to 0.43)
P value	<0.001	<0.001	<0.001	0.357
Changes from baseline to week 24	-2.87±2.34	-2.68±2.27	-2.84±2.32	-0.13 (0.79 to 0.53)
P value	<0.001	<0.001	<0.001	0.696

Values are presented as number (%), mean ± standard deviation, or least-squares mean difference (95% confidence interval).
SU, sulfonylurea; HbA1c, glycosylated hemoglobin; FPG, fasting plasma glucose.